Skip to content

Clinical study of interruption of toxin enterohepatic circulation by bile drainage for the treatment of liver failure due to amatoxin-containing mushrooms

Clinical study of interruption of toxin enterohepatic circulation by bile drainage for the treatment of liver failure due to amatoxin-containing mushrooms

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073442
Enrollment
Unknown
Registered
2023-07-11
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Faiure induced by Amatoxin-containing Mushrooms

Interventions

Treatments Group A:Bile Drainage+Standard Conventional Treatments
Treatments Group B:Standard Conventional Treatments

Sponsors

The First People's Hospital of Yunnan Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years; 2.A definite history of consumption of poisonous mushrooms before the onset of the disease (morphologically confirmed to be amatoxin-containing mushrooms based on the provided mushrooms in kind or photographs, or detection amatoxin in blood or urine); 3. 6h after consuming the poisonous mushroom, digestive symptoms such as poor appetite, nausea, vomiting, abdominal distension, and progressive elevation of liver biochemical and coagulation indexes were observed. Liver function and coagulation were monitored every 8h, and the indexes met the diagnostic criteria for prehepatic failure. 4. duration of disease <= 7d; 5. Agree to participate in this study and sign a written informed consent

Exclusion criteria

Exclusion criteria: Those meeting any of the following criteria were excluded in this study: 1. Hemodynamically unstable, or critically ill with an expected survival time of <24 hours 2.Pregnant or lactating women; 3. The presence of any other condition that the investigator considers inappropriate for inclusion in this trial.

Design outcomes

Primary

MeasureTime frame
28-day mortality rate; In-hospital mortality rate;cure rate;Duration of disease;

Secondary

MeasureTime frame
MELD score;Serious complications related to liver injury;extubation;Bleeding;Infeiction;

Countries

China

Contacts

Public ContactJiawei Geng

The First People's Hospital of Yunnan Province

Jiawei_Geng@kmust.edu.cn+86 138 8875 7766

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026